
[Knowledge and Skills](#skills)
====================

- Experience and original research in virtual screening, molecular dynamics, pharmacophore modeling, virtual library generation, and cheminformatics
- Familiar with the practice, implementation and theory of many of the latest techniques in deep learning, 
including graph neural networks, transformers, and diffusion
- Mentor and manager in the fields of programming, algorithms, mathematics, physical chemistry, and quantum physics  
- First-hand experience with the drug development process, from discovery to first-in-human, including target validation, hit finding, assay development, lead optimization, and DMPK
- Broad experience in data science, including very large data sets, inference, and modeling
- A skilled technical writer, with experience in scientific, technical, and marketing roles 
- A proficient software programmer with experience in a wide range of development roles


[Professional Experience](#experience)
=======================


## Principal Engineer, Molecular Structures, Nobias Therapeutics, 2021–Present

Tasked with integrating physics-informed, atom-level molecular information into the 
company's AI platform, using best practices in cheminformatics, ligand docking, 
molecular dynamics, and protein processing, and with
special attention to machine-learning augmentation. Tools employed include
PyTorch, OpenMM, OpenForcefield, OpenFold, Vina, GNINA, Open Babel, and RDKit. Developed proprietary 
machine-learning models by integrating various techniques, such as natural-language processing (NLP), 
graph convolutional neural networks (GCNN), transformers, 
and variational diffusion models (VDM).


## Senior Director of Platform Technology, Verseon, Fremont, CA, 2018–2021

Maintained responsibilities held under Director, Research and Development, with a focus on further expanding Verseon's pioneering efforts in computational drug development through recruitment, directed research in computational chemistry, and drug program initiation. Collaborated with medicinal chemists and research biologists in guiding Verseon’s anticoagulant program into phase I.

## Director, Research and Development, Verseon, Fremont, CA 2011–2018

Responsible for managing Verseon’s Computational R&D efforts, including planning, budgeting, operations, and recruiting. Contributed to original research in protein modeling, molecular dynamics, forcefield parameterization, and small molecular library generation. Continued to directly contribute to code development efforts. Assisted with target selection. Provided computational, managerial, and statistical support for Verseon’s drug development programs.


## Scientist, Verseon, Fremont, CA 2006–2011

Played a central role in the development and deployment of Verseon’s computational drug-discovery platform. Responsible for the development and maintenance of the company’s proprietary virtual compound library. Primary author of Verseon’s custom LIMS, featuring instrument integration, curve fitting, project workflow, and cheminformatics. Assisted in Verseon’s drug development programs as needed.

## Chief Technologist, BlockRules Ltd., Fremont, CA, 2018–Present

Responsible for establishing and evangelizing the technological
foundation of BlockRules' financial securities platform.

## Postdoctoral Researcher, University of California, Santa Cruz, CA 1994–2006

Contributed to major research efforts as part of the
ATLAS (Large Hadron Collider), BaBar (Stanford Linear Accelerator), 
and ZEUS (Deutsches Elektronen-Synchrotron) Collaborations.
Explored topics in proton computed tomography as a member of
the pCT Collaboration.

## Lecturer in Physics, University of California, Santa Cruz, CA 2000–2000

Organized and taught the graduate course “Introduction to Particle Physics.”

[Computational Experience](#computer)
========================

- Up to date with the latest techniques and practices in deep-learning research and engineering, including implementations employing PyTorch, PyG, Parquet, Arrow and Ray Tune
- Experience with the use and integration of a variety of chemistry toolsets and platforms, including RDKit, OpenMM, OpenBabel, MarvinBeans (ChemAxon), OpenEye, NWChem, PyMOL, Percepta, GROMACS, AmberTools, and MOE
- Proficient in more than a dozen computer languages, including Python, R, c++, and SQL
- Responsible for numerous applications in numerical computing developed for a wide range of research roles
- Broad experience with the practice and theory of data science using a variety of techniques and platforms, including multiple regression, maximum likelihood, decision trees, and neural networks
- Firsthand experience with full-stack web development, including front-end implementations with React, Redux, jQuery, CSS, and SVG, with backend implementations with Python, perl, Node.js, SQL, MongoDB, and Boto
- Direct experience with a wide range of computer hardware and operating systems, old and new
- Familiar with high-performance computing, containers, run-time environments, and system design

[Education](#education)
=========

Ph.D., Physics, Massachusetts Institute of Technology, Cambridge, MA, 1994

B.S., Physics, Northeastern University, Boston, MA, 1987


[Selected Publications and Patents](#publications)
=================================

- Williams, David C. and Inala, Neil "Physics-Informed Generative Model for Drug-like Molecule Conformers." *Journal of Computer-Aided Molecular Design* 64.8 (2024): 2988.
- Short, Kevin M., et al. “Discovery of novel N-acylpyrazoles as potent and selective thrombin inhibitors.” *European Journal of Medicinal Chemistry* (2022): 114855.
- Williams, David C., et al. “Robust ligand-protein docking using an advanced genetic algorithm.” Submitted to *Journal of Computer-Aided Molecular Design.*
- Sivaraja, Mohanram, et al. “VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.” *Thrombosis Research* 190 (2020): 112-121.
- Sivaraja, Mohanram, et al. “Reversible covalent direct thrombin inhibitors.” *PloS one* 13.8 (2018): e0201377.
- Aubert, Bernard, et al. “Observation of a charmed baryon decaying to D0 p at a mass near 2.94 GeV/c2.” *Physical review letters* 98.1 (2007): 012001.
- Schulte, Reinhard W., et al. "Density resolution of proton computed tomography." *Medical Physics* 32.4 (2005): 1035-1046.
- Williams, David C. “The most likely path of an energetic charged particle through a uniform medium.” *Physics in Medicine & Biology* 49.13 (2004): 2899.
- Bosisio, Luciano, et al. "Limits on D0-D0-bar mixing and CP violation from the ratio of lifetimes for decay to K−pi+, K−K+ and pi−pi+." *Physical Review Letters* 91.12 (2003): 121801.
- Short, Kevin M., et al. “Multisubstituted aromatic compounds as serine protease inhibitors.” U.S. Patent No. 10,251,872. 9 Apr. 2019.
- Short, Kevin M., Son Minh Pham, and David Charles Williams. “Halogenopyrazoles as inhibitors of thrombin.” U.S. Patent No. 9,951,025. 24 Apr. 2018.
- Short, Kevin M., et al. “Multisubstituted aromatic compounds as inhibitors of thrombin.” U.S. Patent No. 9,533,967. 3 Jan. 2017.


